Azithromycin to prevent acute lower respiratory infections among Australian and New Zealand First Nations and Timorese children (PETAL trial): study protocol for a multicentre, international, double-blind, randomised controlled trial by Anne B Chang, Keith Grimwood, Yuejen Zhao, Gabrielle B McCallum, Catherine A Byrnes, Heidi Smith-Vaughan, Peter S Morris, Christine Connors, Adrian Trenholme, Shirley Lawrence, Joshua Francis, Kobi L Schutz, Mark D Chatfield, Nevio Sarmento, Robyn L. Marsh, Emily R Bowden, Nicholas Fancourt, Adriano Vieira, Kim M Hare, Dennis Bonney, Felicity Marwick, Bronwyn Karvonen, Carolyn Maclennan, Milena Santos Lay, Endang Soares da Silva

“…Long-term azithromycin was chosen as it reduces ALRI rates by 50% in Australian and New Zealand First Nations children with chronic suppurative lung disease or bronchiectasis. …”
Get full text